Cefepime Hydrochloride/Taniborbactam

N/A

Report date: 2023/09/05 14:09:03
NMEQIDP

Base Information

Drug NameCefepime Hydrochloride/Taniborbactam
Drug Alias NameCefepime+VNRX-5133Cefepime/VNRX-5133VNRX-5133+CefepimeVNRX-5133/CefepimeVNRX-5133/Cefepime Hydrochloride +[8] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > β-lactam antibiotics > Cephalosporins antibiotics
Mechanisms of ActionBeta Lactamase inhibitorsCell wall inhibitorsBacterial penicillin-binding protein inhibitors
TargetsBeta LactamaseBacterial penicillin-binding protein
Therapy Area/IndicationsPyelonephritisUrinary Tract InfectionsPneumonia, Ventilator-Associated +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesUkraine +[15] 
CombinationsYes Cefepime HydrochlorideTaniborbactam
Global Highest StatusNDA/BLA
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesVenatorx Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesEverest Medicines (Suzhou) IncEverest Medicines II LtdMelinta Therapeutics LLC +[5] 
Inactive CompaniesN/A
Active IndicationsPyelonephritisUrinary Tract Infections
Inactive IndicationsPneumonia, Ventilator-AssociatedHealthcare-Associated Pneumonia

Other Information

ATC CodeN/A
Related LinksN/A